Scarica l'app Stockscreener
47.46
0.13%
-0.0339
Precedente Chiudi:
$47.43
Aprire:
$47.18
Volume 24 ore:
368.20K
Relative Volume:
0.33
Capitalizzazione di mercato:
$4.83B
Reddito:
$47.30M
Utile/perdita netta:
$-225.97M
Rapporto P/E:
-20.20
EPS:
-2.35
Flusso di cassa netto:
$-188.86M
1 W Prestazione:
+5.64%
1M Prestazione:
+6.57%
6M Prestazione:
+50.81%
1 anno Prestazione:
+31.07%
Intervallo 1D:
$46.72
$48.15
Intervallo di 1 settimana:
$42.07
$48.19
Portata 52W:
$22.71
$49.82
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Nome
Scholar Rock Holding Corp
Settore
Industria
Telefono
857-259-3860
Indirizzo
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
47.39 | 4.84B | 47.30M | -225.97M | -188.86M | -2.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.94 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.57 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
730.65 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.71 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.05 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Iniziato | Citigroup | Buy |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-10-09 | Iniziato | BofA Securities | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-15 | Iniziato | Leerink Partners | Outperform |
| 2025-08-21 | Ripresa | Jefferies | Buy |
| 2025-07-30 | Ripresa | Raymond James | Strong Buy |
| 2025-07-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-11-26 | Reiterato | H.C. Wainwright | Buy |
| 2024-10-07 | Reiterato | H.C. Wainwright | Buy |
| 2024-03-28 | Iniziato | Raymond James | Strong Buy |
| 2023-10-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-04-03 | Ripresa | Piper Sandler | Overweight |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-07-12 | Iniziato | Truist | Buy |
| 2022-03-23 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-22 | Downgrade | Jefferies | Buy → Hold |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-01-11 | Iniziato | Credit Suisse | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-03-12 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Scholar Rock Holding Corp Borsa (SRRK) Ultime notizie
Fisher Asset Management LLC Has $19.86 Million Stock Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock at TD Cowen Conference: Strategic Vision and Challenges - Investing.com Nigeria
Piper Sandler raises Scholar Rock stock price target on SMA launch - Investing.com India
SRRK: Citigroup Raises Price Target to $58, Maintains Buy Rating | SRRK Stock News - GuruFocus
Citigroup Issues Positive Forecast for Scholar Rock (NASDAQ:SRRK) Stock Price - MarketBeat
Scholar Rock Holding (SRRK) Sees Price Target Raised by Truist S - GuruFocus
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, BMO Capital Markets Analyst Says - MarketBeat
Piper Sandler Raises Price Target for SRRK to $58.00, Maintains Overweight Rating | SRRK Stock News - GuruFocus
Scholar Rock (NASDAQ:SRRK) Sees Unusually-High Trading Volume Following Earnings Beat - MarketBeat
Barclays Raises Price Target for Scholar Rock Holding (SRRK) to $53 | SRRK Stock News - GuruFocus
Piper Sandler Forecasts Strong Price Appreciation for Scholar Rock (NASDAQ:SRRK) Stock - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q4 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Scholar Rock Holding to $55 From $44, Keeps Buy Rating - marketscreener.com
Aisling Capital Management LP Takes $2.87 Million Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Decoding Scholar Rock Holding Corp (SRRK): A Strategic SWOT Insi - GuruFocus
SRRK Technical Analysis & ETF Price Forecast - Intellectia AI
Raymond James Maintains Strong Buy on Scholar Rock (SRRK) Mar 2026 - Meyka
Scholar Rock (NASDAQ: SRRK) posts 2025 loss, expands debt capacity - Stock Titan
Barclays raises Scholar Rock stock price target to $53 on debt deal - Investing.com
Scholar Rock (SRRK) Revises Financial Results for Q4 2025 - GuruFocus
Truist raises Scholar Rock stock price target on manufacturing progress By Investing.com - Investing.com Australia
Truist raises Scholar Rock stock price target on manufacturing progress - Investing.com
Raymond James reiterates Scholar Rock stock Strong Buy on debt facility - Investing.com
Scholar Rock Q4 Earnings Call Highlights - MarketBeat
Scholar Rock (NASDAQ:SRRK) Shares Gap UpTime to Buy? - MarketBeat
Scholar Rock Q4 2025 Earnings Call Transcript - MarketBeat
Scholar Rock Holding (SRRK) Receives Reiterated 'Buy' Rating fro - GuruFocus
Scholar Rock (NASDAQ:SRRK) Given Buy Rating at HC Wainwright - MarketBeat
Scholar Rock Holding Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Wedbush Adjusts Price Target on Scholar Rock to $56 From $50, Maintains Outperform Rating - marketscreener.com
Earnings call transcript: Scholar Rock Q4 2025 shows slight EPS beat, stock rises - Investing.com
Scholar Rock (SRRK) Q4 2025 Earnings Transcript - AOL.com
Scholar Rock Holding Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Scholar Rock (SRRK) Poised for FDA Resubmission of Apitegromab - GuruFocus
Vanguard Group Inc. Has $183.03 Million Stock Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock (NASDAQ:SRRK) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Q4 Loss, Awaits Apitegromab Approval in 2026 - ChartMill
Scholar Rock FY income from operations USD -384.645 million - marketscreener.com
Scholar Rock Advances Apitegromab Toward SMA Commercial Launch - TipRanks
Scholar Rock (SRRK) 2025 loss widens as SMA programs advance - Stock Titan
Scholar Rock Holding 10-K: Operating loss $384.6M, Net loss $377.9M - TradingView
Scholar Rock Q4 Net Loss Widens - marketscreener.com
SRRKForm S-8Securities to be offered to employees in employee benefit plans - ADVFN Ltd
Earnings Flash (SRRK) Scholar Rock Posts Q4 Net Loss $0.88 a Share, vs. FactSet Est of $0.89 Loss - marketscreener.com
Apitegromab and SRK-439 lead Scholar Rock (NASDAQ: SRRK) neuromuscular pipeline - Stock Titan
Scholar Rock Holding: Q4 Earnings Insights - Benzinga
Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - marketscreener.com
CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Stock Titan
Scholar Rock Holding Corporation $SRRK Shares Purchased by Rafferty Asset Management LLC - MarketBeat
SRRK Earnings History & Surprises | EPS & Revenue Results | SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK) - ChartMill
Scholar Rock investors brace for earnings amid FDA resubmission push By Investing.com - Investing.com UK
Scholar Rock Holding Corp Azioni (SRRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):